Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
---|---|---|---|---|---|---|
EMD Serono | Avelumab | Bavencio | 2017-03-23 | |||
Incyte | Retifanlimab | Zynyz | 2023-03-22 | $1.135 M | Q2/23-Q1/24 | |
Merck Sharp & Dohme | Avelumab | Bavencio | 2017-09-18 |
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
---|---|---|---|---|---|